Published in final edited form as:

J Am Chem Soc. 2012 November 14; 134(45): 18834–18842. doi:10.1021/ja309172t.

A Biomimetic Route for the Construction of the [4+2] and [3+2] Core Skeletons of the Dimeric Pyrrole-Imidazole Alkaloids and the Asymmetric Synthesis of Ageliferins

Xiao Wang[†], Xiaolei Wang, Xianghui Tan[‡], Jianming Lu[§], Kevin W. Cormier, Zhiqiang Ma, and Chuo Chen

Division of Chemistry, Department of Biochemistry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States

Abstract

The pyrrole-imidazole alkaloids have fascinated chemists for decades because of their unique structures. The high nitrogen and halogen contents and the densely functionalized skeletons make their laboratory synthesis challenging. We describe herein an oxidative method for accessing the core skeletons of two classes of pyrrole-imidazole dimers. This synthetic strategy was inspired by the putative biosynthesis pathways and its development was facilitated by computational studies. Using this method, we have successfully prepared ageliferin, bromoageliferin, and dibromoageliferin in their natural enantiomeric form.

Introduction

The pyrrole-imidazole alkaloids, often referred to as the oroidin family of alkaloids, are a group of structurally diverse natural products formed through oxidation, cyclization, and oligomerization of oroidin and its debrominated congeners (**1**).¹ For example, ageliferins (**2**),² massadines (**3**),³ and benzosceptrins (**4**)⁴ are the [4+2], [3+2], and [2+2] dimerization products of **1**, respectively (figure 1). While cycloadditions of **1** are generally believed to be involved in the biosynthesis of **2–4**,⁵ attempts to dimerize **1** in the test tube failed to deliver these alkaloids because of the mismatched electronic properties.⁶ Recently, Molinski, Romo, and co-workers used cell-free extracts of the pyrrole-imidazole alkaloid-producing sponges to induce the dimerization of hymenidine (**1b**) in vitro giving the [2+2] dimer benzosceptrin (**4**).⁷ They further proposed that the dimerization of **1** is promoted by a single-electron transfer (SET). We have been interested in studying the biomimetic synthesis of the pyrrole-imidazole alkaloids and proposed that the dimerization of **1** proceeds through a radical mechanism.⁸ Agreeing to the hypothesis put forth by Molinski and Romo, we believed that a SET oxidation of **1** would give radical cation **1**^{•+} that is highly active toward cycloadditions. We have further shown that both the [4+2] and [3+2] dimerization products could be obtained from an oxidative radical cyclization reaction in model systems. We describe

Correspondence to: Chuo Chen.

Corresponding Author Chuo.Chen@UTSouthwestern.edu.

[†]Department of Chemistry and Biochemistry, the University of California, San Diego

[‡]ChemPacific Corporation, Baltimore, Maryland.

[§]PerkinElmer, Boston, Massachusetts.

ASSOCIATED CONTENT

Supporting Information. Experimental procedures, characterization data, and computational details. This material is available free of charge via the Internet at <http://pubs.acs.org>.

herein the design of this biomimetic synthetic strategy and its application to the asymmetric synthesis of ageliferins (**2**).

The unique structures of the dimeric pyrrole-imidazole alkaloids have, over several decades, inspired chemists to develop numerous synthetic strategies and methods. These include work from the groups of Overman,⁹ Carreira,¹⁰ Romo,¹¹ Lovely,¹² Ohta,¹³ Austin,¹⁴ Baran,¹⁵ Birman,¹⁶ Haran,¹⁷ Gin,¹⁸ Gleason,¹⁹ Namba-Williams-Nishizawa²⁰ and us.⁸ Notably, the synthesis of the [2+2] dimer has been accomplished by Baran and coworkers^{15a} and Birman and co-workers,¹⁶ the [3+2] dimers by Baran and co-workers,^{15c-h} and the [4+2] dimers by Baran and co-workers^{15b} and us.^{8c} It should also be noted that Ohta and co-workers have used a biomimetic Diels–Alder approach to achieve the racemic synthesis of 12,12'-dimethyl-**2a**,¹³ and Romo and co-workers¹¹ and Lovely and co-workers¹² have independently developed a biomimetic skeletal rearrangement approach to synthesize the core skeleton of **3**. Complementary to other reported approaches, our biomimetic approach comprises a manganese(III)-promoted oxidation of a β -ketoester and a radical tandem cyclization to yield the skeleton of the [4+2] or [3+2] dimer with control.^{8a} Its development was guided by computational studies. The realization of this intramolecular radical tandem cyclization reaction suggests that the SET-mediated oroidin dimerization is chemically viable.

Results and Discussion

Research Design

We hypothesized that the biogenic dimerization of **1** proceeds through a radical mechanism as shown in Scheme 1. Activation of **1** by a SET oxidation gives radical cation **1**^{•+}, which undergoes a [4+2] (path a) or a [3+2] (path b) cycloaddition with **1** to give **5** or **6**. Subsequent SET and further transformations yield **2** and **3**. This cycloaddition reaction can be either a concerted or a stepwise process.

To test this hypothesis, we designed a model system to study if the radical cycloaddition of **1** and **1**^{•+} is viable. We envisioned that the reaction efficiency could be improved significantly by tethering **1** and **1**^{•+}, and replacing the olefin group with an enol. We thus chose **7** as the model system for **1**. We anticipated that a SET oxidation of **7** would give radical cation **7**^{•+}, which resembles **1**^{•+}/**1**. After losing a proton, radical **7**[•] could undergo a 5-exo followed by a 6-endo cyclization to afford the ageliferin core skeleton **8**, or a 5-exo followed by another 5-exo cyclization to afford the massadine core skeleton **9**.

Model Studies

We sought to initiate the radical cascade of **7**[•] by oxidizing **7** with a Mn(III) salt.²¹ The first intramolecular Mn(III)-promoted radical cyclization of a β -dicarbonyl compound was reported by Corey and Kang in 1984 as part of their ginkgolide synthesis project.²² Later, Snider and co-workers achieved asymmetric Mn(III) radical addition reactions by using chiral auxiliaries,²³ and Yang and co-workers found that chelating lanthanide triflates could enhance both the diastereoselectivity and the reaction rate.^{24,25}

Our work began with studying the oxidation of **10** (X=H or Cl). The α -chlorine atom was incorporated to prevent over-oxidation. To our disappointment, treating **10** with various Mn(III) and Ce(IV) salts led only to complete decomposition (Scheme 2). We found that the imidazolinone group was destroyed but the olefinic group remained intact, indicating that the oxidation occurred without radical cyclization. We suspected that radical **10**[•] adopts the anti conformation as indicated in Scheme 2 to minimize the dipole moment. A 1,5-hydrogen abstraction of the benzylic proton occurred and destroyed the imidazolinone group. This anti

conformation could possibly be destabilized by introducing an α -alkyl group (e.g., **11**[•]). Indeed, we found that oxidation of **11** with Mn(OAc)₃ proceeded cleanly to afford **12** in 63% yield. The ageliferin skeleton was obtained as the only product.^{8a}

With the working conditions for the biomimetic [4+2] dimerization reaction in hand, we next studied the asymmetric synthesis of the ageliferin core skeleton using an allylic stereocenter as the controlling element (Scheme 3).²⁶ We found that oxidation of **13** gave **15** and **16** in a 2:1 ratio, indicating that the two faces of the olefin are slightly differentiated. We then tested if the C9-C10 relative stereochemistry could be controlled by the olefin geometry to afford the nagelamide skeleton.²⁷ Surprisingly, we found that oxidation of **14** gave the same anti products **15** and **16** in a 2:3 ratio, suggesting that the two cyclizations proceeded stepwisely and the 6-endo cyclization was slower than the epimerization of the C10 radical. The relative configurations of **15** and **16** were determined by ¹H NMR experiments. This assignment is supported by the following experiments. Removal of the TIPS group of **15** and **16** followed by oxidation of the resulting alcohol provided ketones having all identical physical properties except the direction of optical rotation.^{8a}

We proposed that the stereochemical information of the (*Z*)-olefin could be retained by constraining it in a cyclic system. Pleasingly, we found that oxidation of **17** yielded **18** with the desired syn C9-C10 configuration corresponding to that of nagelamides. The diastereoselectivity of the reaction was also improved as **18** was the only observed product.

The proposed mechanism for the oxidation of **11** is shown in Scheme 4. It has been reported that the cis-products are kinetically favored whereas the trans-products are thermodynamically favored in the Mn(III)-promoted oxidative cyclization of allylic β -ketoesters.²⁸ We therefore believe that the cis configuration at the 5,6-ring junction in **12** resulted from trapping of the kinetic cyclization product of **11**[•] (i.e., **19**). The loss of the olefinic stereochemical information in the oxidation of **14** suggests that epimerization of the radical center of **19** is faster than the second cyclization. While radical **19** could be first oxidized to a cation and then cyclized to **12**, we consider the ionic cyclization less likely because of the mismatched polarization of acylimidazolinone. Also, addition of Cu(OAc)₂, which is known to accelerate the oxidation of secondary radicals by 350 times,²⁹ had no effect on this reaction.

The observed regioselectivity for the cyclizations of **11** is rather unusual. The 5-exo cyclization is normally kinetically favored over the 6-endo cyclization for alkyl radicals while the opposite is true for α -acyl radicals. Based on the seminal computational studies by Houk and co-workers, the planarity of α -acyl radicals is maintained in the transition states, causing the reversed regioselectivity.³⁰ We obtained **12** from **11** through a 5-exo cyclization of an α -acyl radical (**11**[•]→**19**) and a 6-endo cyclization of an alkyl radical (**19**→**21**). We are particularly interested in the mechanism of the second radical cyclization step because it determines the formation of the [4+2] versus the [3+2] dimer skeleton. This cyclization could proceed through a direct 6-endo cyclization (**19**→**21**), a 5-exo cyclization followed by a 1,2-shift (**19**→**20**→**21**), or a reversible 5-exo cyclization of **19** giving **21** as a thermodynamic product (**20**↔**19**→**21**). We therefore analyzed all these three pathways with DFT calculations to gain insights into this cyclization reaction (Figure 2).

Curran, Snider, and co-workers previously showed that Mn is not bound to the substrate during the radical cyclization.³¹ The computational studies are therefore less complicated because the transition metal is not involved. We further simplified the computational work by replacing the benzyl and phenyl groups of **19**–**21** with a methyl group and examined the reactions of radicals **22**–**24**. Because the stereochemical information of C11' in **20** and C15'

in **21** is lost in the product **12**, we calculated the energy levels for both diastereomeric pathways.

We first performed the calculations with Spartan using three different methods: UHF/6-31G*, UB3LYP/6-31G**//UHF/6-31G* and UB3LYP/6-31G**. ^{30c,32} The geometries obtained from the UB3LYP/6-31G** calculations were further refined with Gaussian using the UB3LYP functional and the 6-311G** basis set. The corresponding energy diagram is shown in Figure 2. The 6-endo cyclization was found to be both kinetically and thermodynamically favored by all these methods; however, the HF/DFT hybrid method significantly underestimated the activation energies of the 6-endo cyclization pathway. ³³ According to the UB3LYP/6-311G** calculations, the activation barrier for the 6-endo cyclization is 5.7 or 4.1 kcal/mol lower than the 5-exo cyclization for **22**, depending on the configuration of the newly formed stereocenters. The activation barrier for the 1,2-shift is forbiddingly high (44.7 or 50.8 kcal/mol).

We note that the 6-endo cyclization product **24** is 16.7 or 11.4 kcal/mol more stable than the 5-exo cyclization product **23**. These results agree with the reported ESR studies on the captodative stabilization of radicals, ³⁴ which predict **24** to be 16.8 kcal/mol more stable than **23**. The synergetic stabilization of the amino and carbonyl groups results in a 10.8 kcal/mol captodative effect. We further examined the atomic spin densities for the transition states that lead to **23** and **24** and found that the captodative stabilization also greatly contributes to the kinetic preference for the 6-endo cyclization ³³ whereas the steric effects may also play a role. ³⁵

Based on these results, we predicted that installation of an electron-withdrawing group to the 15'-position would introduce captodative stabilization to the 5-exo cyclization pathway and results in a switch of the pathway selectivity. Computational studies indicated that the introduction of a chloro (**25**) or a cyano group (**26**) would lower the activation barrier of the 5-exo cyclization pathway without affecting the 6-endo cyclization pathway (Figure 3). We subsequently validated this hypothesis experimentally and identified the stereochemistry of **20** and **21**. We therefore focus herein the computational results corresponding to the observed stereochemistry. Our calculations suggest that the 6-endo cyclization pathway is favored for **22** (Oimid) by 4.1 kcal/mol, but the 5-exo cyclization pathways is favored for **25** (Oimid-Cl) and **26** (Oimid-CN) by 3.7 and 6.2 kcal/mol, respectively. The 6-endo cyclization product of **25** is also predicted to undergo a barrierless elimination of the chlorine atom to afford the imidazolinone directly.

We were pleased to find that the experimental results are fully in line with the computational predictions (Scheme 5). Oxidation of the chloro-substituted **27** afforded the 5-exo cyclization product **28** and the mono-cyclized product **29** in a 1:1.2 ratio. The structure of **28** has been confirmed by single crystal X-ray analysis. ^{8a} Replacing the phenyl group of **27** with a methyl group gave similar results. Oxidation of **30** gave **31** and **32** in a 1:1.4 ratio. We reasoned that trans-**29** and trans-**32** were formed because the second cyclization was hindered by the chlorine atom, rendering the retro-cyclization of the first 5-exo cyclization competitive. A trans-lactone was thus formed, further slowing down the second 5-exo cyclization because of torsional strains.

The computational studies suggested that stronger captodative stabilization could be obtained for the 5-exo cyclization pathway with a cyano-substituted imidazolinone. Indeed, oxidation of **33** gave the 5-exo cyclization product **34** as the only product. ³⁵ This reaction delivered the massadine core skeleton directly through a 5-exo/5-exo radical tandem cyclization but with an undesired spiro configuration. This observed stereo-chemistry supports the proposed conformation of **11'** and **19** shown in Scheme 4.

Because the oxidation of **33** gave the massadine core skeleton with an undesired spiro configuration, we briefly explored the potential of constructing the massadine core skeleton through oxidative ring-contraction of the ageliferin core skeleton, a method that was also studied by the groups of Romo,¹¹ Lovely,¹² and Baran⁵¹ (Scheme 6). Unfortunately, the oxidation of **12** with mCPBA proceeded slowly from the undesired β -face, giving also **28**. The reaction rate was low due to the presence of a pseudo-axial phenyl group on the β -face while the concaved α -face of **12** is not accessible.

Synthesis of Ageliferins

We sought to accomplish the synthesis of ageliferins (**2**) using the biomimetic radical cyclization reaction described above.³⁶ We initially planned to use imidazolinone as the aminoimidazole surrogate. However, we were not able to convert imidazolinone to aminoimidazole at various stages. Activating imidazolinone with thionation, methylation, sulfonation, or phosphorylation followed by attacking with a nitrogen nucleophile all failed. Model studies suggested that the activation of imidazolinone occurred predominantly on the nitrogen instead of the oxygen atom. We next planned to use thioimidazolinone as the aminoimidazolinone surrogate but found it too labile to be introduced early. We therefore decided to explore the feasibility of using azidoimidazole as a protected aminoimidazole.

We first calculated the activation barrier (UB3LYP/6-311G**) of the Mn(III)-promoted oxidative cyclization for imidazole **35** and azidoimidazole **36** to evaluate if the aromaticity of imidazole would prevent the cyclization to occur. Encouragingly, the reaction was predicted to proceed as easily as compared to imidazolinone **22** (Figure 4). Consistent with the computational predictions, our model studies showed that oxidative cyclization of imidazole **37** and azidoimidazole **39** gave the ageliferin core skeletons **38** and **40** in 40% and 42% yield, respectively (Scheme 7). The mono-cyclized product was also obtained in ca. 15% yield in both reactions.

We have also tested if the biomimetic oxidative ring-contraction reaction could be realized with **40**. While oxidation of azidoimidazole **40** occurred without ring-contraction, reducing the azido group restored the migratory reactivity. Treating **40** with PPh₃ gave a stable phosphine imide that reacted with mCPBA to give **41** (Scheme 8). Similar to the oxidation of **12**, the oxidant approached from the β -face to afford the undesired spiro configuration. Removal of the lactone group and reduction of the azido group by PPh₃ gave **42**. Subsequent oxidation with mCPBA afforded **43**, which also bears the undesired spiro configuration. The structures of **41** and **43** were confirmed by single crystal X-ray analyses.³⁷

Returning to the synthesis of ageliferins, we started our work by coupling azidoimidazole **44** with allylic ester **45** and prepared **46** (Scheme 9).^{8b} Oxidative cyclization of azidoimidazole **46** proceeded uneventfully to give the ageliferin core skeleton **47**. The best results were obtained when the oxidation was carried out with Mn(OAc)₃ in acetic acid at 50–60 °C or with Mn(picolate)₃ in methanol at 90 °C. Purification of **47** was found challenging and reverse-phase silica gel was used to minimize material loss. While **47** can be obtained as a 2.5–3:1 mixture of the C9' diastereomers in 18–25% isolated yield, we found that using crude **47** directly for the following steps gave a higher overall yield of **49**.

The stereochemical outcomes of the oxidation of **46** are in sharp contrast to those of the oxidation of **13**. The existence of **47** as a mixture of C9' diastereomers suggests that, for **46**, the second, 6-endo radical cyclization was relatively slow and the first, 5-exo cyclization became reversible. Since the oxidative cyclization of the azidoimidazole analog of **13** did not yield a mixture of C9' diastereomers,³³ we concluded that the slowing of the 6-endo

cyclization is because of the increased steric effects imposed by the C10 side-chain instead of the strong aromaticity of azidoimidazole.

Decarboxylation of the crude mixture of **47** yielded a single diastereomer. In contrast to **42**, the *cis* product was found to be thermodynamically more stable. We further found that the *cis*/*trans* ratio is sensitive to the size of the C10 side-chain, which may gear the C9 side-chain and increase the equatorial-equatorial eclipsing of the C9 and C9' side-chains for the *trans* isomer.

Converting the revealed hydroxyl group to an amino group was surprisingly difficult. Eventually we installed this critical nitrogen atom through activating the hydroxyl group by mesylation. Converting **48** to an iodide followed by displacing the iodide by an azide afforded **49** in 11–13% yield over 9 steps. Introducing the azido group by a Mitsunobu reaction or reacting **48** directly with an azide resulted mainly in elimination.

With the N7 and N7' nitrogen functional groups in place, we next sought to introduce the two pyrrole side-chains. A Staudinger reduction was used to reveal the N7 amine of **49**. We found that only the alkyl triphenylphosphine imide was hydrolyzed under the neutral conditions. The imidazolyl phosphine imide was moderately stable even under acidic conditions, rendering it a suitable protecting group for amino-imidazole.³⁸ The acetonide and Boc protecting groups could be selectively hydrolyzed to give **50**. The excess triphenylphosphine and triphenylphosphine oxide from the Staudinger reduction were easily removed by washing **50** with diethyl ether.

For the synthesis of ageliferin (**2a**) and dibromoageliferin (**2c**), we introduced the pyrrole groups to the less hindered N7 and N7' amines of **50** selectively. With a careful control of the reaction time, **51** was obtained as the major products in 66% yield. The N7'-mono-acylated product, obtained as the minor product in ca. 20% yield, could be recycled to improve the overall yield of **51**. For the synthesis of bromoageliferin (**2b**), the dibromopyrrole side-chain was first introduced to the N7 amine after the Staudinger reduction of **49**. Next, the N7' amine was released and the bromopyrrole group was introduced to give **51b**.

To construct the second aminoimidazole group, we first installed a guanidine group on **51** and oxidized the hydroxyl group by 2-iodoxybenzoic acid (IBX). The resulting aldehyde cyclized smoothly with the guanidine to yield **52**. When the reaction was conducted at small scale, this cyclization was slow but can be facilitated by adding 0.5 equivalent of trifluoroacetic acid. The cyclization product **52** was directly purified by HPLC without workup to prevent decomposition induced by the IBX oxidation byproduct.

To complete the synthesis, the C9' configuration of **52** was corrected through a slow equilibration under acidic conditions (60–72 h, d.r.>10:1). The C10' carbonyl group was then removed by sequential reductions to afford **53**. The BOM protecting group was cleaved by treating **53** with boron trichloride. The resulting chloromethyl group was hydrolyzed with ammonia in acetonitrile-water. Using the methanolic ammonia solution for this hydrolysis resulted in the conversion of the chloromethyl group to a methoxymethyl (MOM) group. Finally, the triphenylphosphine imide group was hydrolyzed by hydro-chloric acid at 60 °C to afford the ageliferins (**2**).

Summary

Through computational and experimental studies, we demonstrated that the biogenic dimerization of oroidin (**1a**) may proceed through a radical mechanism. Activation of **1** by SET oxidation is likely used by enzymes to promote the otherwise difficult cycloaddition

reactions. We further designed a biomimetic synthesis of the [4+2] dimer of **1** using a manganese(III)-promoted radical tandem cyclization reaction. Our synthetic strategy allowed for a flexible introduction of the pyrrole side-chains with different bromine patterns, leading to the asymmetric synthesis of ageliferin (**2a**), bromoageliferin (**2b**), and dibromoageliferin (**2c**). We are currently investigating the biological functions of these natural products.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial Support was provided by NIH (NIGMS R01-GM079554, R01-GM079554-S1, NCCAM R01-AT006889), the Welch Foundation (I-1596), and UT Southwestern. C.C. is a Southwestern Medical Foundation Scholar in Biomedical Research. We thank Prof. Joseph Ready for the access to the Gaussian 03 suite of programs. The calculations with Gaussian 09 were supported in part by the National Science Foundation through TeraGrid resources provided by National Center for Supercomputing Applications (NCSA) under CHE090129. The X-ray analysis of **41** and **43** was performed by Dr. Muhammed Yousufuddin (University of Texas at Arlington) and Dr. Joseph Ziller (University of California, Irvine), respectively.

REFERENCES

1. a Hoffmann H, Lindel T. *Synthesis*. 2003; 35:1753–1783. b Jacquot DEN, Lindel T. *Curr. Org. Chem.* 2005; 9:1551–1565. c Du H, He Y, Sivappa R, Lovely CJ. *Synlett*. 2006:965–992. d Köck M, Grube A, Seiple IB, Baran PS. *Angew. Chem. Int. Ed.* 2007; 46:6586–6594. e Weinreb SM. *Nat. Prod. Rep.* 2007; 24:931–948. [PubMed: 17898890] f Arndt H-D, Riedrich M. *Angew. Chem. Int. Ed.* 2008; 47:4785–4788. g Heasley B. *Eur. J. Org. Chem.* 2009:1477–1489. h Forte B, Malgesini B, Piutti C, Quartieri F, Scolaro A, Papeo G. *Mar. Drugs*. 2009; 7:705–753. [PubMed: 20098608] i Gaich T, Baran PS. *J. Org. Chem.* 2010; 75:4657–4673. [PubMed: 20540516] j Al-Mourabit A, Zancanella MA, Tilvi S, Romo D. *Nat. Prod. Rep.* 2011; 28:1229–1260. [PubMed: 21556392]
2. a Rinehart KL. *Pure Appl. Chem.* 1989; 61:525–528. b Keifer PA, Schwartz RE, Koker MES, Robert G, Hughes J, Rittschof D, Rinehart KL. *J. Org. Chem.* 1991; 56:2965–2975. c Kobayashi J, Tsuda H, Murayama T, Nakamura H, Ohizumi Y, Ishibashi M, Iwamura M. *Tetrahedron*. 1990; 46:5579–5586.
3. a Nishimura S, Matsunaga S, Shibazaki M, Suzuki K, Furihata K, van Soest RWM, Fusetani N. *Org. Lett.* 2003; 5:2255–2257. [PubMed: 12816422] b Grube A, Immel S, Baran PS, Köck M. *Angew. Chem. Int. Ed.* 2007; 46:6721–6724. 8107. c Zhang H, Khalil Z, Conte MM, Plisson F, Capon RJ. *Tetrahedron Lett.* 2012; 53:3784–3787.
4. a Walker RP, Faulkner DJ, Engen DV, Clardy J. *J. Am. Chem. Soc.* 1981; 103:6772–6773. b Appenzeller J, Tilvi S, Martin M-T, Gallard J-F, El-bitar H, Dau ETH, Debitus C, Laurent D, Moriou C, Al-Mourabit A. *Org. Lett.* 2009; 11:4874–4877. [PubMed: 19863148] c Tilvi S, Moriou C, Martin M-T, Gallard J-F, Sorres J, Patel K, Petek S, Debitus C, Ermolenko L, Al-Mourabit A. *J. Nat. Prod.* 2010; 73:720–723. [PubMed: 20166736] d Kubota T, Araki A, Yasuda T, Tsuda M, Fromont J, Aoyama K, Mikami Y, Wälchli MR, Kobayashi J. i. *Tetrahedron Lett.* 2009; 52:7268–7270.
5. ^a Ref. 4a. ^b Ref 2b. Olofson A, Yakushijin K, Horne DA. *J. Org. Chem.* 1997; 62:7918–7919. [PubMed: 11671892] Kinnel RB, Gehrken H-P, Swali R, Skoropowski G, Scheuer PJ. *J. Org. Chem.* 1998; 63:3281–3286. Al Mourabit A, Potier P. *Eur. J. Org. Chem.* 2001:237–243. Wang Y-G, Morinaka BI, Reyes JCP, Wolff JJ, Romo D, Molinski TF. *J. Nat. Prod.* 2010; 73:428–434. [PubMed: 20095632] Ma Z, Lu J, Wang X, Chen C. *Chem. Commun.* 2011; 47:427–429. Feldman KS, Nuriye AY, Li J. *J. Org. Chem.* 2011; 76:5042–5060. [PubMed: 21574600] For an alternative hypothesis, see: Baran PS, O'Malley DP, Zografos AL. *Angew. Chem. Int. Ed.* 2004; 43:2674–2677. Baran PS, Li K, O'Malley DP, Mitsos C. *Angew. Chem. Int. Ed.* 2006; 45:249–252. Northrop BH, O'Malley DP, Zografos AL, Baran PS, Houk KN. *Angew. Chem. Int. Ed.* 2006; 45:4126–

- 4130.O'Malley DP, Li K, Maue M, Zografos AL, Baran PS. *J. Am. Chem. Soc.* 2007; 129:4762–4775. [PubMed: 17375928]
6. ^a Ref. 4a. Pöverlein C, Breckle G, Lindel T. *Org. Lett.* 2006; 8:819–821. [PubMed: 16494449]
7. a Stout EP, Wang Y-G, Romo D, Molinski TF. *Angew. Chem. Int. Ed.* 2012; 51:4877–4881. b Stout EP, Morinaka BI, Wang Y-G, Romo D, Molinski TF. *J. Nat. Prod.* 2012; 75:527–530. [PubMed: 22455452]
8. Tan X, Chen C. *Angew. Chem. Int. Ed.* 2006; 45:4345–4348. ^b Ref. 5g. Wang X, Lu ZMJ, Tan X, Chen C. *J. Am. Chem. Soc.* 2011; 133:15350–15353. [PubMed: 21888421] Lu J, Tan X, Chen C. *J. Am. Chem. Soc.* 2007; 129:7768–7769. [PubMed: 17539649]
9. a Overman LE, Rogers BN, Tellew JE, Trenkle WC. *J. Am. Chem. Soc.* 1997; 119:7159–7160. b Lanman BA, Overman LE, Paulini R, White NS. *J. Am. Chem. Soc.* 2007; 129:12896–12900. [PubMed: 17902668]
10. a Starr JT, Koch G, Carreira EM. *J. Am. Chem. Soc.* 2000; 122:8793–8794. b Chinigo GM, Carreira ABEM. *Org. Lett.* 2011; 13:78–81. [PubMed: 21138327] c Breder A, Chinigo GM, Waltman AW, Carreira EM. *Chem. Eur. J.* 2011; 17:12405–12416. [PubMed: 21932242]
11. a Dilley AS, Romo D. *Org. Lett.* 2001; 3:1535–1538. [PubMed: 11388860] b Dransfield PJ, Dilley AS, Wang S, Romo D. *Tetrahedron.* 2006; 62:5223–5247. c Wang S, Dilley AS, Poullennec KG, Romo D. *Tetrahedron.* 2006; 62:7155–7161. d Zancanella MA, Romo D. *Org. Lett.* 2008; 10:3685–3688. [PubMed: 18693745]
12. a Lovely CJ, Du H, Dias HVR. *Org. Lett.* 2001; 3:1319–1322. [PubMed: 11348224] b Lovely CJ, Du H, He Y, Dias HVR. *Org. Lett.* 2004; 6:735–738. [PubMed: 14986962] c Sivappa R, Hernandez NM, He Y, Lovely CJ. *Org. Lett.* 2007; 9:3861–3864. [PubMed: 17803309]
13. a Kawasaki I, Sakaguchi N, Fukushima N, Fujioka N, Nikaido F, Yamashita M, Ohta S. *Tetrahedron Lett.* 2002; 43:4377–4380. b Kawasaki I, Sakaguchi N, Khadeer A, Yamashita M, Ohta S. *Tetrahedron.* 2006; 62:10182–10192.
14. Koenig SG, Miller SM, Leonard KA, Löwe RS, Chen BC, Austin DJ. *Org. Lett.* 2003; 5:2203–2206. [PubMed: 12816409]
15. Baran PS, Zografos AL, O'Malley DP. *J. Am. Chem. Soc.* 2004; 126:3726–3727. [PubMed: 15038721] ^b Ref. 5i-l. Yamaguchi J, Seiple IB, Young IS, O'Malley DP, Maue M, Baran PS. *Angew. Chem. Int. Ed.* 2008; 47:3578–3580. O'Malley DP, Yamaguchi J, Young IS, Seiple IB, Baran PS. *Angew. Chem. Int. Ed.* 2008; 47:3581–3583. Su S, Seiple IB, Young IS, Baran PS. *J. Am. Chem. Soc.* 2008; 130:16490–16491. [PubMed: 19049446] Seiple IB, Su S, Young IS, Lewis CA, Yamaguchi J, Baran PS. *Angew. Chem. Int. Ed.* 2010; 49:1095–1098. Su S, Rodriguez RA, Baran PS. *J. Am. Chem. Soc.* 2011; 133:13922–13925. [PubMed: 21846138] Seiple IB, Su S, Young IS, Nakamura A, Yamaguchi J, Jørgensen L, Rodriguez RA, O'Malley DP, Gaich T, Köck M, Baran PS. *J. Am. Chem. Soc.* 2011; 133:14710–14726. [PubMed: 21861522]
16. Birman VB, Jiang X-T. *Org. Lett.* 2004; 6:2369–2371. [PubMed: 15228281]
17. a Garrido-Hernandez H, Nakadai M, Vimolratana M, Li Q, Doundoulakis T, Harran PG. *Angew. Chem. Int. Ed.* 2005; 44:765–769. b Li Q, Hurley P, Ding H, Roberts AG, Akella R, Harran PG. *J. Org. Chem.* 2009; 74:5909–5919. [PubMed: 19603820] c Ding H, Roberts AG, Harran PG. *Angew. Chem. Int. Ed.* 2012; 51:4340–4343.
18. Bultman MS, Ma J, Gin DY. *Angew. Chem. Int. Ed.* 2008; 47:6821–6824.
19. a Hudon J, Cernak TA, Ashenhurst JA, Gleason JL. *Angew. Chem. Int. Ed.* 2008; 47:8885–8888. b Cernak TA, Gleason JL. *J. Org. Chem.* 2008; 73:102–110. [PubMed: 18067312]
20. a Namba K, Kaihara Y, Yamamoto H, Imagawa H, Tanino K, Williams RM, Nishizawa M. *Chem. Eur. J.* 2009; 15:6560–6563. [PubMed: 19492366] b Namba K, Inai M, Sundermeier U, Greshock TJ, Williams RM. *Tetrahedron Lett.* 2010; 51:6557–6559. [PubMed: 21286237]
21. a Snider BB. *Chem. Rev.* 1996; 96:339–363. [PubMed: 11848756] b Snider BB. *Tetrahedron.* 2009; 65:10738–10744. c Melikyan GG. *Org. React.* 1997; 49:427–675.
22. Corey EJ, Kang M.-c. *J. Am. Chem. Soc.* 1984; 106:5384–5385.
23. Zhang Q, Mohan RM, Cook L, Kazanis S, Peisach D, Foxman BM, Snider BB. *J. Org. Chem.* 1993; 58:7640–7651.
24. Yang D, Ye X-Y, Xu M, Pang K-W, Cheung K-K. *J. Am. Chem. Soc.* 2000; 122:1658–1663.
25. Renaud P, Gerster M. *Angew. Chem. Int. Ed.* 1998; 37:2562–2579.

26. Hoffmann RW. Chem. Rev. 1989; 89:1841–1860.
27. Endo T, Tsuda M, Okada T, Mitsuhashi S, Shima H, Kikuchi K, Mikami Y, Fromont J, Kobayashi J. J. Nat. Prod. 2004; 67:1262–1267. [PubMed: 15332839]
28. Sung K, Wang YY. J. Org. Chem. 2003; 68:2771–2778. [PubMed: 12662051]
29. Heiba EI, Dessau RM. J. Am. Chem. Soc. 1971; 93:524–527.
30. a Spellmeyer DC, Houk KN. J. Org. Chem. 1987; 52:959–974. b Broeker JL, Houk KN. J. Org. Chem. 1991; 56:3651–3655. c Leach AG, Wang R, Wohlhieter GE, Khan SI, Jung ME, Houk KN. J. Am. Chem. Soc. 2003; 125:4271–4278. [PubMed: 12670249]
31. Curran DP, Morgan TM, Schwartz CE, Snider BB, Dombroski MA. J. Am. Chem. Soc. 1991; 113:6607–6617.
32. Wong MW, Radom L. J. Phys. Chem. 1995; 99:8582–8588.
33. See Supporting Information for details.
34. Welle FM, Beckhaus H-D, Rüchardt C. J. Org. Chem. 1997; 62:552–558. [PubMed: 11671448]
35. We believe that the steric effects are less important in determining the 5-exo/6-endo selectivity of the second cyclization. Replacing the cyano group of **33** with a methyl group did not result in a switch of the cyclization pathway. Instead, a complex mixture of reaction products was obtained from the oxidation of **54**.

36. We previously reported the synthesis of *ent*-**2a** using *ent*-**45** (Ref. 8c). The natural enantiomer of **2a** is now synthesized for biological studies.
37. Based on the crystal structures of **41** and **43**, the triphenylphosphine imide of aminoimidazole exists in the indicated form with no distortion and no stabilization from the N14' nitrogen atom. The typical crystallographic N=P, N(sp²)-P, and N(sp³)-P bond length is 1.597(0.018), 1.651(0.024), and 1.683(0.005) Å, respectively. The N=P bond length is 1.599 and 1.596 Å, and the C-N=P bond angle is 123.1° and 124.1° in the crystals of **41** and **43**, respectively.
38. The use of triphenylphosphine imide as a protecting group has been reported: Liu ST, Liu CY. J. Org. Chem. 1992; 57:6079–6080.

Clathrocin (**1a**): $X^1, X^2 = H, H$
 Hymenidin (**1b**): $X^1, X^2 = Br, H$
 Oroidin (**1c**): $X^1, X^2 = Br, Br$

Agliferin (**2a**): $X^1, X^2 = H, H$
 Bromoagliferin (**2b**): $X^1, X^2 = H, Br$
 Dibromoagliferin (**2c**): $X^1, X^2 = Br, Br$

Massadine (**3a**): $X = OH$
 Massadine chloride (**3b**): $X = Cl$

Benzosceptrin A (**4a**): $X^1, X^2 = H, H$
 Benzosceptrin B (**4b**): $X^1, X^2 = Br, H$
 Benzosceptrin C (**4c**): $X^1, X^2 = Br, Br$

Figure 1.
 Structures of selected pyrrole-imidazole alkaloids.

Scheme 1.

A divergent biomimetic approach for the synthesis of the [4+2] and [3+2] pyrrole-imidazole dimers.

Realization of the Mn(III)-promoted oxidative 5-exo/6-endo cyclization.

Scheme 3.

Model studies of the Mn(III)-promoted oxidative cyclization reaction.

Scheme 4.

The proposed mechanism of the Mn(III)-promoted oxidative 5-exo/6-endo radical cyclization.

Figure 2.
The energy diagram for the 6-endo and the 5-exo cyclizations of **22**, and the 1,2-shift of **23**.

Figure 3.
 The energy diagram for the 6-endo versus 5-exo cyclization for **22**, **25** and **26**.

Scheme 5.

Switching the reaction pathway through controlling the captodative stabilization of radicals.

Scheme 6.

Conversion of the ageliferin core to the massadine core by an oxidative ring-contraction reaction.

Figure 4.

Comparing the activation barriers of the radical cyclization of imidazolinone **22**, imidazole **35**, and azidoimidazole **36**.

Scheme 7.
Mn(III)-promoted oxidative cyclization of imidazole substrates.

Scheme 8.

The biomimetic oxidative ring-contraction reactions.

Scheme 9.
Synthesis of ageliferins (**2**).